Stocks move in premarket on trial results, upgrades and cyberattack update
Premarket stocks move on earnings, analyst calls, and clinical trial results. See which names jumped or fell before the opening bell and why.
Shares of several companies moved in premarket trading on Tuesday after earningsrelated updates, analyst ratings, and clinical trial results.
Roivant Sciences rose after reporting Phase 2 results for subsidiary Pulmovant's mosliciguat, which the company said showed a meaningful reduction in pulmonary vascular resistance in patients with pulmonary hypertension linked to interstitial lung disease. Lockheed Martin gained after UBS upgraded the defense contractor to buy, citing earnings growth potential.
Other names moved lower. Novartis fell after Phase 3 data showed no significant improvement for its deldesiran drug in patients with myotonic dystrophy type 1. Peloton Interactive declined after Morgan Stanley downgraded the stock, saying the company faces ongoing headwinds in the fitness market. Boston Scientific also slipped after warning that a recent cyberattack is likely to affect 2026 sales and profit targets.
Bloom Energy rose ahead of its planned addition to the S&P 500, while quantum computing stocks climbed after the U.S. announced minority equity stakes in several companies tied to a CHIPS Act deal.